Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors
肿瘤微环境的衰老相关分泌表型 (SASP) 调节作为 KRAS 驱动肿瘤的治疗策略
基本信息
- 批准号:10474386
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcademiaAdvisory CommitteesAntigen PresentationAntigensAwardBiologicalBiologyBypassCDK4 geneCTLA4 geneCancer BiologyCancer EtiologyCell AgingCell CommunicationCell Cycle ArrestCellsCessation of lifeCharacteristicsClinicCytotoxic ChemotherapyDiseaseEffectivenessEndothelial CellsEngineeringEnvironmentFacultyFibroblastsFunctional disorderFunding MechanismsGeneticGenetic TranscriptionGenetically Engineered MouseGoalsHumanImmuneImmune systemImmunityImmunocompetentImmunologic SurveillanceImmunooncologyImmunosuppressionIn VitroIndividualInfiltrationInternationalInterventionInterviewK-ras mouse modelKRAS2 geneLabelLung NeoplasmsMEKsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMediatingMemorial Sloan-Kettering Cancer CenterMentorsMethodsModelingMolecularMolecular TargetMonitorNK Cell ActivationNatural Killer CellsOrganPathway interactionsPatientsPharmacologyPhenotypePositioning AttributePredispositionPremalignant CellProcessProductionReporterResearchResearch ProposalsResourcesRoleSignal TransductionSolid NeoplasmStromal NeoplasmT cell responseTP53 geneThe SunTherapeuticTimeTissuesTraining ProgramsTumor AntigensTumor Suppressor ProteinsUnited StatesVascular remodelingVascularizationVisualizationWorkcancer cellcancer therapycareercareer developmentclinically relevantdisorder controleffective therapyflexibilityimmune checkpoint blockadeimmunoregulationimprovedin vivoinhibitorintravital microscopymolecular targeted therapiesmouse modelmutantneoplastic cellnovel therapeutic interventionpancreatic cancer cellspancreatic neoplasmpatient derived xenograft modelpatient subsetspleiotropismprogrammed cell death protein 1programsrecruitresponserestorationscreeningsenescencestandard of caretargeted agenttherapy outcometreatment responsetumortumor initiationtumor microenvironmenttumorigenesis
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal describes a training program to advance my academic career in the study of the tumor
suppressive barriers that are bypassed during progression to malignancy and how they can be restored for
therapeutic benefit in established tumors. Cellular senescence, a tumor suppressive process involving durable
cell cycle arrest and activation of a senescence-associated secretory phenotype (SASP), can recruit immune
cells to target and clear tumors. During my postdoctoral work, I identified molecularly targeted agents that can
reestablish senescence, SASP, and a unique form of Natural Killer (NK) immune surveillance that drives
tumor regressions and long-term survival in KRAS mutant lung cancer. This research proposal aims to
characterize and exploit the SASP to sustain immune and stromal control of RAS-driven solid tumors, with the
goal of identifying new or potentiating existing therapies for these deadly diseases. My expertise in mouse
modeling, target discovery, and the biology of senescence and immune surveillance that I have acquired
during my postdoctoral studies puts me in a unique position to significantly contribute to elucidating the role of
senescence in cancer therapy and identifying new therapeutic strategies for KRAS mutant tumors.
To accomplish the research outlined in this application, I will leverage modular and immune competent mouse
models of KRAS mutant lung and pancreas cancer, as well as methods to reestablish senescence, SASP, and
NK cell immune surveillance that I have already developed in the Lowe lab. In Aim 1, with the hypothesis that
methods to overcome NK cell dysfunction are needed to establish disease control, I will explore mechanisms
and strategies to further potentiate NK cell responses in KRAS mutant lung cancer through transcriptional and
immune profiling and functional screening. In Aim 2, the organ-specific and pleiotropic effects of the SASP on
tumor-stromal interactions in pancreas tumors will be interrogated to determine SASP factors necessary for
productive tumor control and how they impact the efficacy of standard-of-care therapies. Together, these
approaches will unveil new ways by which the SASP can be used to control KRAS-driven tumors.
To achieve the goals of this award, I will be mentored by Dr. Scott Lowe and guided by an exceptional advisory
committee I have established at MSKCC. Dr. Lowe is an internationally recognized expert in cancer biology,
and is focused on understanding tumor suppressor networks through the use of sophisticated mouse models.
The advisory committee, constituted by Dr. Lowe, Dr. Sun, Dr. Rosen, Dr. Iacobuzio-Donahue, and Dr. Rudin
will monitor and support my transition to independence. Moreover, they will provide invaluable guidance during
the process of applying and interviewing for faculty positions. MSKCC will provide me institutional support,
including resources for experimental work and career development, as well as an engaging scientific
environment. My objective is to obtain a faculty position to develop an impactful research program, where the
K99/R00 funding mechanism will serve as an essential step in my transition to independence in academia.
!
!
!
项目概要/摘要
该提案描述了一项培训计划,以促进我在肿瘤研究方面的学术生涯
在恶性肿瘤进展过程中绕过的抑制屏障以及如何恢复它们
对已形成的肿瘤有治疗效果。细胞衰老,一种涉及持久性的肿瘤抑制过程
细胞周期停滞和衰老相关分泌表型(SASP)的激活,可以招募免疫系统
细胞靶向并清除肿瘤。在我的博士后工作期间,我发现了分子靶向药物可以
重建衰老、SASP 和一种独特形式的自然杀伤 (NK) 免疫监视,从而驱动
KRAS 突变肺癌的肿瘤消退和长期生存。本研究计划旨在
表征和利用 SASP 来维持 RAS 驱动的实体瘤的免疫和基质控制,
目标是确定针对这些致命疾病的新疗法或增强现有疗法。我对鼠标的专业知识
我所掌握的建模、目标发现以及衰老和免疫监视生物学
在我的博士后研究期间,我处于一个独特的位置,可以为阐明
癌症治疗中的衰老并确定 KRAS 突变肿瘤的新治疗策略。
为了完成本申请中概述的研究,我将利用模块化和免疫能力强的小鼠
KRAS 突变肺癌和胰腺癌模型,以及重建衰老、SASP 和
我已经在 Lowe 实验室开发了 NK 细胞免疫监视。在目标 1 中,假设
需要克服 NK 细胞功能障碍的方法来建立疾病控制,我将探索机制
以及通过转录和转录进一步增强 KRAS 突变肺癌中 NK 细胞反应的策略
免疫分析和功能筛查。在目标 2 中,SASP 对器官特异性和多效性的影响
将对胰腺肿瘤中的肿瘤-基质相互作用进行研究,以确定胰腺癌所需的 SASP 因子
有效的肿瘤控制以及它们如何影响标准治疗的疗效。在一起,这些
方法将揭示 SASP 可用于控制 KRAS 驱动的肿瘤的新方法。
为了实现该奖项的目标,我将得到 Scott Lowe 博士的指导和杰出顾问的指导
我在 MSKCC 设立了委员会。 Lowe 博士是国际公认的癌症生物学专家,
并专注于通过使用复杂的小鼠模型来了解肿瘤抑制网络。
顾问委员会由 Lowe 博士、Sun 博士、Rosen 博士、Iacobuzio-Donahue 博士和 Rudin 博士组成
将监督并支持我向独立的过渡。此外,他们将在期间提供宝贵的指导。
申请和面试教师职位的过程。 MSKCC 将为我提供机构支持,
包括实验工作和职业发展的资源,以及引人入胜的科学
环境。我的目标是获得一个教职职位来开发一个有影响力的研究项目,其中
K99/R00资助机制将成为我向学术界独立过渡的重要一步。
!
!
!
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy.
- DOI:10.1016/j.semcancer.2022.02.005
- 发表时间:2022-11
- 期刊:
- 影响因子:14.5
- 作者:Chibaya, Loretah;Snyder, Jarin;Ruscetti, Marcus
- 通讯作者:Ruscetti, Marcus
Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer.
先天免疫激动剂的纳米粒子递送与衰老诱导剂相结合,介导 T 细胞对胰腺癌的控制。
- DOI:10.1101/2023.09.18.558307
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Chibaya,Loretah;Lusi,ChristinaF;DeMarco,KellyD;Kane,GriffinI;Brassil,MeghanL;Parikh,ChaitanyaN;Murphy,KatherineC;Li,Junhui;Naylor,TianaE;Cerrutti,Julia;Peura,Jessica;Pitarresi,JasonR;Zhu,LihuaJulie;Fitzgerald,Katherine
- 通讯作者:Fitzgerald,Katherine
Senescent macrophages: A new "old" player in lung cancer development.
- DOI:10.1016/j.ccell.2023.05.008
- 发表时间:2023-07-10
- 期刊:
- 影响因子:50.3
- 作者:Zhou, Lin;Ruscetti, Marcus
- 通讯作者:Ruscetti, Marcus
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marcus A. Ruscetti其他文献
Marcus A. Ruscetti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marcus A. Ruscetti', 18)}}的其他基金
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors
肿瘤微环境的衰老相关分泌表型 (SASP) 调节作为 KRAS 驱动肿瘤的治疗策略
- 批准号:
10200265 - 财政年份:2020
- 资助金额:
$ 24.9万 - 项目类别:
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors
肿瘤微环境的衰老相关分泌表型 (SASP) 调节作为 KRAS 驱动肿瘤的治疗策略
- 批准号:
10250565 - 财政年份:2020
- 资助金额:
$ 24.9万 - 项目类别:
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors
肿瘤微环境的衰老相关分泌表型 (SASP) 调节作为 KRAS 驱动肿瘤的治疗策略
- 批准号:
9805196 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Conference: Rethinking how language background is described in academia and beyond
会议:重新思考学术界及其他领域如何描述语言背景
- 批准号:
2335912 - 财政年份:2024
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
ADVANCE Catalyst: Virtual Observatory of Culture for Equity in Academia at the University of Puerto Rico Rio Piedras (VoCEA)
ADVANCE Catalyst:波多黎各 Rio Piedras 大学学术界平等文化虚拟观察站 (VoCEA)
- 批准号:
2214418 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
Comprehensive development strategy of modality-specific "intellectual property" and "cultivation" with an eye on "pharmaceutical affairs" in academia drug discovery
学术界新药研发着眼“药事”的模式“知识产权”与“培育”综合发展策略
- 批准号:
23K02551 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating Research Advancement for Investigators Underrepresented in Academia
加速学术界代表性不足的研究人员的研究进展
- 批准号:
10746315 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Planning: HBCU-UP: Strengthening Data Science Research Capacity and Education Programs through Academia-Industry Partnership
规划:HBCU-UP:通过学术界与工业界合作加强数据科学研究能力和教育计划
- 批准号:
2332161 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer
从学术界到商界:针对 HPV 相关癌症的新型疗法的开发
- 批准号:
10813323 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Academics4Rail: Building a community of railway scientific researchers and academia for ERJU and enabling a network of PhDs (academia teaming with industry)
Academys4Rail:为ERJU建立铁路科研人员和学术界社区并建立博士网络(学术界与工业界合作)
- 批准号:
10087488 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
Academics4Rail: Building a Community of Railway Scientific Researchers and Academia for ERJU and Enabling a Network of PhDs (Academia Teaming with Industry)
Academys4Rail:为二院建立铁路科研人员和学术界社区并启用博士网络(学术界与工业界合作)
- 批准号:
10102850 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
EU-Funded
Exploring the overall picture of industry-academia-government collaboration: A spectrum of knowledge transfer through formal and informal channels
探索产学官合作的整体图景:通过正式和非正式渠道进行的一系列知识转移
- 批准号:
22K01692 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Fostering Ethical Neurotechnology Academia-Industry Partnerships: A Stakeholder Engagement and Toolkit Development Project
促进道德神经技术学术界与工业界的伙伴关系:利益相关者参与和工具包开发项目
- 批准号:
10655632 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:














{{item.name}}会员




